These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

906 related articles for article (PubMed ID: 26267412)

  • 1. Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis.
    Zhang Q; Chen J; Yu X; Cai G; Yang Z; Cao L; Hu C; Guo X; Sun J; Chen J
    Breast Cancer; 2016 Sep; 23(5):732-9. PubMed ID: 26267412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases.
    Niwińska A; Murawska M; Pogoda K
    Cancer; 2010 Sep; 116(18):4238-47. PubMed ID: 20549816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
    Larsen PB; Kümler I; Nielsen DL
    Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology.
    Kaplan MA; Isikdogan A; Koca D; Kucukoner M; Gumusay O; Yildiz R; Dayan A; Demir L; Geredeli C; Kocer M; Arslan UY; Inal A; Akman T; Coskun U; Sener N; Inanc M; Elkiran ET; Ozdemir NY; Durnalı AG; Suner A; Alici S; Tarhan MO; Boruban C; Oksuzoglu B; Urakci Z
    Breast Cancer; 2014 Nov; 21(6):677-83. PubMed ID: 23335064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
    Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
    J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
    Cortés J; Dieras V; Ro J; Barriere J; Bachelot T; Hurvitz S; Le Rhun E; Espié M; Kim SB; Schneeweiss A; Sohn JH; Nabholtz JM; Kellokumpu-Lehtinen PL; Taguchi J; Piacentini F; Ciruelos E; Bono P; Ould-Kaci M; Roux F; Joensuu H
    Lancet Oncol; 2015 Dec; 16(16):1700-10. PubMed ID: 26596672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer.
    Bartsch R; Rottenfusser A; Wenzel C; Dieckmann K; Pluschnig U; Altorjai G; Rudas M; Mader RM; Poetter R; Zielinski CC; Steger GG
    J Neurooncol; 2007 Dec; 85(3):311-7. PubMed ID: 17557136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Retrospective Study on the Efficacy of Trastuzumab in HER2-Positive and Tamoxifen-Refractory Breast Cancer with Brain Metastasis.
    Zhang C; Wang L; Wang L; Cui S
    BioDrugs; 2016 Feb; 30(1):33-40. PubMed ID: 26792291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases.
    Lin NU; Freedman RA; Ramakrishna N; Younger J; Storniolo AM; Bellon JR; Come SE; Gelman RS; Harris GJ; Henderson MA; Macdonald SM; Mahadevan A; Eisenberg E; Ligibel JA; Mayer EL; Moy B; Eichler AF; Winer EP
    Breast Cancer Res Treat; 2013 Nov; 142(2):405-14. PubMed ID: 24197661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain metastases in HER2-positive metastatic breast cancer patients who received chemotherapy with or without trastuzumab.
    Kaplan MA; Ertugrul H; Firat U; Kucukoner M; İnal A; Urakci Z; Pekkolay Z; Isikdogan A
    Breast Cancer; 2015 Sep; 22(5):503-9. PubMed ID: 24385387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome Evaluation of HER2 Breast Cancer Patients with Limited Brain Metastasis.
    Pessina F; Navarria P; Cozzi L; Franceschini D; Tomatis S; Clerici E; Ascolese AM; DE Rose F; Bello L; Masci G; Santoro A; Scorsetti M
    Anticancer Res; 2017 Dec; 37(12):7057-7062. PubMed ID: 29187495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changing Natural History of HER2-Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies.
    Mounsey LA; Deal AM; Keith KC; Benbow JM; Shachar SS; Zagar T; Dees EC; Carey LA; Ewend MG; Anders CK
    Clin Breast Cancer; 2018 Feb; 18(1):29-37. PubMed ID: 28867445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyrotinib combining with radiotherapy on breast cancer with brain metastasis.
    Ma X; Li Y; Zhao Z; Li L; Gao C; Liu D; Li B; Zhao B
    Exp Biol Med (Maywood); 2023 Jan; 248(2):106-116. PubMed ID: 36533572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab-based Retreatment after Lapatinib in Heavily Pretreated HER2 Positive Metastatic Breast Cancer: an Anatolian Society of Medical Oncology Study.
    Uncu D; Bayoglu IV; Arslan UY; Kucukoner M; Artac M; Koca D; Oguz A; Demirci U; Arpaci E; Dogan M; Kucukzeybek Y; Turker I; Isikdogan A; Guler T; Zengin N
    Asian Pac J Cancer Prev; 2015; 16(9):4127-31. PubMed ID: 25987098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer.
    Park IH; Ro J; Lee KS; Nam BH; Kwon Y; Shin KH
    Ann Oncol; 2009 Jan; 20(1):56-62. PubMed ID: 18664558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 significance and treatment outcomes after radiotherapy for brain metastases in breast cancer patients.
    Wolstenholme V; Hawkins M; Ashley S; Tait D; Ross G
    Breast; 2008 Dec; 17(6):661-5. PubMed ID: 18571923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer.
    Gori S; Inno A; Fiorio E; Foglietta J; Ferro A; Gulisano M; Pinotti G; Gubiotti M; Cavazzini MG; Turazza M; Duranti S; De Simone V; Iezzi L; Bisagni G; Spazzapan S; Cavanna L; Saggia C; Bria E; Cretella E; Vici P; Santini D; Fabi A; Garrone O; Frassoldati A; Amaducci L; Saracchini S; Evangelisti L; Barni S; Gamucci T; Mentuccia L; Laudadio L; Zoboli A; Marchetti F; Bogina G; Lunardi G; Boni L
    PLoS One; 2015; 10(9):e0136731. PubMed ID: 26340098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer--a phase II study.
    Shawky H; Tawfik H
    J Egypt Natl Canc Inst; 2014 Dec; 26(4):187-94. PubMed ID: 25294797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
    Farhat F; Kattan JG; Ghosn M
    Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.
    Cadoo KA; Morris PG; Cowell EP; Patil S; Hudis CA; McArthur HL
    Clin Breast Cancer; 2016 Dec; 16(6):487-493. PubMed ID: 27622751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.